MedTech Innovation through Clinician-Engineer Collaboration: AccuPulse Cardiac Pulsed Field Ablation System by Acora Medical Garners Spotlight at Beijing Clinical Evaluation Symposium
AccuPulse
Developer of products in the field of cardiac electrophysiology
Medical-Engineering Collaboration, Technological Innovation
On September 27, 2025, the Clinical Application Evaluation Seminar and the Inaugural Meeting of the Application Evaluation Branch of the China Medical Equipment Association were successfully held at the Beijing Medical Science and Technology Clinical Application Evaluation Center.AccuPulse Medical Technology Co., Ltd., as a representative of innovative medical technology enterprises, was invited to attend the conference and showcased its independently developed and already approved core products, such as the AccuPulse Cardiac Pulse Ablation System. During the conference, the PFA Expert Consensus Launch Meeting and live animal experiment demonstrations performed excellently, receiving high praise from the attending experts.
Focus on Innovation
Building a New Future for Medical Device Evaluation Together
Hou Yan, Chairman of the China Medical Equipment Association
This conference summarized and展望ed the work direction of the Application Evaluation Branch of the China Medical Equipment Association.Hou Yan, Chairman of the China Medical Equipment AssociationIn the speech, full affirmation was given to the fruitful achievements made by the branch in the past four years in building a clinical evaluation platform for medical equipment, promoting the integration of medical and engineering fields, and standard formulation. It was emphasized that in the new era, we must adhere to the clinical value orientation, promote the transformation of innovative achievements, and help China's medical equipment industry achieve leading development.
Cai Kui, President of the Application Evaluation Branch of the China Medical Equipment Association
Cai Kui, President of the Application Evaluation BranchIn his work report and inaugural speech, he pointed out that the branch will continue to deepen the collaboration between medical and engineering fields in the future, and build a Chinese-style medical device application evaluation system. He particularly emphasized the need to focus on cutting-edge innovative technologies such as Pulsed Field Ablation (PFA), and rely on the branch platform to unite clinical experts, research institutions, and corporate forces to jointly promote the scientific evaluation and clinical application of new technologies and products, injecting new momentum into the development of the industry.
Expert Consensus Initiation:
PFA Technology Leads New Advances in Atrial Fibrillation Treatment
Long Deyong, Director of the Arrhythmia Center at Beijing Anzhen Hospital, Capital Medical University
The launch meeting of "Expert Consensus on the Comprehensive Value Assessment of Pulsed Field Ablation for the Treatment of Atrial Fibrillation," as one of the key sessions of the conference, has drawn significant attention. This project aims to scientifically evaluate the comprehensive clinical value of PFA, a disruptive technology, with a thematic presentation delivered by Long Deyong, Director of the Arrhythmia Center at Beijing Anzhen Hospital, Capital Medical University.
Director Long DeyongIntroduces the policy background of China establishing a full life cycle value evaluation system for medical devices, and highly evaluates the unique advantages of pulsed field ablation technology in atrial fibrillation treatment, such as high safety, good tissue selectivity, and short operation time.He specifically shared the one-year follow-up results of the clinical study on the AccuPulse Cardiac Pulse Field Ablation System, with an effectiveness rate of 87.7%, fully demonstrating its excellent clinical potential.
Swipe left and right to view
During the live broadcast demonstration of PFA animal experiments after the launch of the expert consensus,Director Long Deyong and his teamDemonstration using AccuPulse's PFA system in the specially designated animal laboratory at the conference.Expressed high satisfaction with its stability, flexibility, efficiency, and safety demonstrated in this animal experiment.AccuPulse Cardiac Pulse Ablation System Showcases Multiple Outstanding Technical Advantages, Attracting Many Experts to Stop and Exchange Ideas.
Voltage Comparison Before and After Ablation and Schematic Diagram of Pulmonary Vein Electrical Isolation
Precision Ablation:Unique electrode-tissue contact indication function ensures the accuracy of ablation points.
High Efficiency Operation:Single pulse discharge <0.2 seconds, significantly shortening operation time;
Stable Output:The bipolar biphasic pulse waveform remains stable, effectively avoiding arc formation;
Flexible Control:7.5F ultra-thin shaft offers excellent passability, reducing tissue damage;
About AccuPulse Medical
Since its establishment in 2020, AccuPulse Medical Technology Co., Ltd. has developed nearly 10 product pipelines based on new technologies such as pulsed field ablation (PFA) and innovative 3D mapping, covering the complete process of diagnosis and treatment for atrial fibrillation, premature ventricular contractions, and other arrhythmia ablations. The company is always committed to providing safer, more efficient, and more precise minimally invasive interventional treatment solutions for atrial fibrillation patients worldwide through technological innovation.
The successful participation in this conference further consolidated AccuPulse Medical Technology Co., Ltd.'s industry influence in the golden track of pulsed electric field ablation.In the future, AccuPulse will actively respond to the association's call, closely cooperate with clinical experts and industry peers, and jointly promote the scientific evaluation and clinical application of innovative medical devices.Contribute to the construction of Healthy China.